SCHEMBL355814

SCHEMBL355814

CCCc1cnc(N2CCC(n3cc(F)c4c(Nc5ccc(C(=O)N6CC[C@@H](O)C6)cc5F)ncnc43)CC2)nc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 3/20 0.51
KMT2A Q03164 4/20 0.42
MEN1 O00255 2/20 0.42
CYP3A4 P08684 1/20 0.38
CYP2C9 P11712 1/20 0.38
LRRK2 Q5S007 2/20 0.37
TYRO3 Q06418 5/20 0.36
PDE4B Q07343 1/20 0.36
PDGFRB P09619 1/20 0.36
KDR P35968 1/20 0.36
MERTK Q12866 3/20 0.36
AXL P30530 2/20 0.36
FLT3 P36888 2/20 0.36
ERBB2 P04626 1/20 0.35
WDR5 P61964 2/20 0.35
MKNK2 Q9HBH9 1/20 0.34
MAP2K1 Q02750 1/20 0.34
MAP4K4 O95819 1/20 0.34
NTRK1 P04629 1/20 0.34
PDGFRA P16234 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL355815 1.00 GPR119 (0.51) GPR119KMT2AMEN1CYP3A4CYP2C9
SCHEMBL10172642 1.00 GPR119 (0.51) GPR119KMT2AMEN1CYP3A4CYP2C9
SCHEMBL356718 0.94 GPR119 (0.44) GPR119KMT2AMEN1CYP3A4CYP2C9
SCHEMBL355773 0.94 GPR119 (0.44) GPR119KMT2AMEN1CYP3A4CYP2C9
SCHEMBL355772 0.94 GPR119 (0.44) GPR119KMT2AMEN1CYP3A4CYP2C9
SCHEMBL10171884 0.94 GPR119 (0.51) GPR119KMT2AMEN1CYP3A4CYP2C9
SCHEMBL10172704 0.94 GPR119 (0.51) GPR119KMT2AMEN1CYP3A4CYP2C9
SCHEMBL10171830 0.91 PDE4B (0.39) GPR119KMT2ACYP3A4CYP2C9LRRK2
SCHEMBL10172633 0.90 GPR119 (0.43) GPR119CYP3A4CYP2C9PDGFRBKDR
SCHEMBL10172162 0.90 GPR119 (0.43) GPR119CYP3A4CYP2C9PDGFRBKDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US claimed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP claimed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US claimed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 GPR119 1/4885KMT2A 2953/4885MEN1 4883/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.